Literature DB >> 7742165

Influence of the behaviour pattern on the nocebo response of healthy volunteers.

M D Drici1, F Raybaud, C De Lunardo, P Iacono, P Gustovic.   

Abstract

The occurrence of a nocebo effect after placebo administration to healthy volunteers in a Phase I trial was analysed according to their type of personality (Bortner Rating Scale). More subjects with a behaviour pattern A (competitive and aggressive) (50%) described subjective side effects of the placebo than type B subjects (17%, P = 0.03). The volunteers who had nocebo effect had a higher Bortner score (BS) than did placebo non-responsive subjects (P = 0.05). The BS was 205 for paramedical staff, 189 for medical and dentistry students, 173 for non-science students and 161 for science students (P < 0.04). The nocebo response was not statistically correlated with professional status. These results suggest that volunteer's type of personality might influence the reporting of subjective symptoms after placebo, and therefore impair the evaluation of new drugs in Phase I clinical trials.

Mesh:

Year:  1995        PMID: 7742165      PMCID: PMC1364964          DOI: 10.1111/j.1365-2125.1995.tb04434.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  The personality structure of 'normal' volunteers.

Authors:  C J Ball; P M McLaren; P J Morrison
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

2.  The nocebo reaction.

Authors:  W P KENNEDY
Journal:  Med World       Date:  1961-09

3.  The role of conditioning and verbal expectancy in the placebo response.

Authors:  Nicholas J Voudouris; Connie L Peck; Grahame Coleman
Journal:  Pain       Date:  1990-10       Impact factor: 6.961

4.  Placebo effects on mind and body.

Authors:  M R Lavin
Journal:  JAMA       Date:  1991-04-03       Impact factor: 56.272

5.  Should we tell trial patients that they might receive placebo?

Authors:  E Skovlund
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

6.  A short rating scale as a potential measure of pattern A behavior.

Authors:  R W Bortner
Journal:  J Chronic Dis       Date:  1969-07

Review 7.  Type A behavior pattern and coronary disease risk. Update and critical evaluation.

Authors:  K A Matthews; S G Haynes
Journal:  Am J Epidemiol       Date:  1986-06       Impact factor: 4.897

8.  Correlation of type A behaviour with adrenergic receptor density: implications for coronary artery disease pathogenesis.

Authors:  J P Kahn; A S Perumal; R J Gully; T M Smith; T B Cooper; D F Klein
Journal:  Lancet       Date:  1987-10-24       Impact factor: 79.321

9.  Predictors of placebo response: a retrospective analysis.

Authors:  C S Wilcox; J B Cohn; R D Linden; J F Heiser; P B Lucas; D L Morgan; D DeFrancisco
Journal:  Psychopharmacol Bull       Date:  1992

Review 10.  [Nocebo--the opposite of placebo].

Authors:  B Kaada
Journal:  Tidsskr Nor Laegeforen       Date:  1989-03-10
View more
  11 in total

1.  Comment on: "Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy".

Authors:  Abdullah Kaya; Yakup Aksoy; Mehmet Koray Sevinç; Oktay Diner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-21       Impact factor: 3.117

2.  Increase in body mass index from normal weight to overweight in a cross-sectional sample of healthy research volunteers.

Authors:  Amber B Courville; Meagan DiVito; Lindsay Moyer; Anna Rossinoff; Caitlin Royster; Tricia Psota; Elaine Ayres; Kirsten L Zambell
Journal:  Nutr Res       Date:  2014-10-20       Impact factor: 3.315

3.  Negative predictors of clinical response to triptans in patients with migraine.

Authors:  M Ishii; Y Sakairi; H Hara; A Imagawa; S Shimizu; J Takahashi; A Nagamine; Y Naito; Y Masuda; S Usami; Y Kiuchi
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

Review 4.  Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.

Authors:  M D Drici; N Clément
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  The Effects of Health Anxiety and Litigation Potential on Symptom Endorsement, Cognitive Performance, and Physiological Functioning in the Context of a Food and Drug Administration Drug Recall Announcement.

Authors:  Len Lecci; Gary Ryan Page; Julian R Keith; Sarah Neal; Ashley Ritter
Journal:  Front Psychol       Date:  2022-06-13

Review 6.  Neurobiological mechanisms of placebo responses.

Authors:  Jon-Kar Zubieta; Christian S Stohler
Journal:  Ann N Y Acad Sci       Date:  2009-03       Impact factor: 5.691

Review 7.  Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.

Authors:  Mourad F Rezk; Burkhard Pieper
Journal:  Rheumatol Ther       Date:  2017-10-14

8.  Differential Classical Conditioning of the Nocebo Effect: Increasing Heat-Pain Perception without Verbal Suggestions.

Authors:  Anne-Kathrin Bräscher; Dieter Kleinböhl; Rupert Hölzl; Susanne Becker
Journal:  Front Psychol       Date:  2017-12-13

9.  The nocebo effect of drugs.

Authors:  Sara Planès; Céline Villier; Michel Mallaret
Journal:  Pharmacol Res Perspect       Date:  2016-03-17

10.  How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions.

Authors:  Meriem Manaï; Henriët van Middendorp; Dieuwke S Veldhuijzen; Tom W J Huizinga; Andrea W M Evers
Journal:  Pain Rep       Date:  2019-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.